Topics:
Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Leukemia • Myeloproliferative Neoplasms • Hematology
Is IDH inhibitor therapy approved for CMML or MDS/MPN overlap with IDH1/2 mutation?
Elderly patient with CMML-2 dysplastic subtype that is not tolerating/responding well to first-line Azacitadine. IDH2 mutation was discovered on bone marrow NGS panel. Has anyone used IDH inhibitor in this population outside AML?